Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
暂无分享,去创建一个
Ravinder Nath | Firas Mourtada | Sou-Tung Chiu-Tsao | David S Followill | Mark J Rivard | Ali S Meigooni | Christopher S Melhus | Rowan M Thomson | Melvin A Astrahan | S. Chiu‐Tsao | D. Followill | M. Rivard | F. Mourtada | M. Astrahan | R. Nath | A. Meigooni | D. Rogers | P. Finger | R. Thomson | C. Melhus | D W O Rogers | Paul T Finger | Mary E Napolitano | M. Napolitano | D. Rogers
[1] R. Emery,et al. Three-dimensional ultrasonography of choroidal melanoma: localization of radioactive eye plaques. , 1998, Archives of ophthalmology.
[2] J. Harbour,et al. Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. , 2008, Archives of ophthalmology.
[3] Ravinder Nath,et al. Comparison of dose calculation methods for brachytherapy of intraocular tumors. , 2010, Medical physics.
[4] M. Rivard,et al. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs. , 2008, Medical physics.
[5] B. Katz,et al. Gamma knife radiosurgery in neuro-ophthalmology , 2003, Current opinion in ophthalmology.
[6] F. Ballester,et al. An approach to using conventional brachytherapy software for clinical treatment planning of complex, Monte Carlo-based brachytherapy dose distributions. , 2009, Medical physics.
[7] A. Markoe,et al. INTRAOPERATIVE ECHOGRAPHIC LOCALIZATION OF IODINE 125 EPISCLERAL RADIOACTIVE PLAQUES FOR POSTERIOR UVEAL MELANOMA , 1996, Retina.
[8] M. Rivard. Monte Carlo radiation dose simulations and dosimetric comparison of the model 6711 and 9011 125I brachytherapy sources. , 2009, Medical physics.
[9] C. Shields,et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. , 2002, Ophthalmology.
[10] P. Lommatzsch,et al. Treatment of juxtapapillary melanomas. , 1991, The British journal of ophthalmology.
[11] P. Finger,et al. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy , 2005, British Journal of Ophthalmology.
[12] W. Hartsell,et al. Review of eye plaque dosimetry based on AAPM Task Group 43 recommendations. American Association of Physicists in Medicine. , 1998, International journal of radiation oncology, biology, physics.
[13] S. Nag,et al. Custom-made "Nag" eye plaques for 125I brachytherapy. , 2003, International journal of radiation oncology, biology, physics.
[14] R. Taylor,et al. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy. , 2008, Medical physics.
[15] C. Shields,et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. , 2002, American journal of ophthalmology-glaucoma.
[16] B. Damato,et al. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. , 2005, International journal of radiation oncology, biology, physics.
[17] D. Jaffray,et al. Improving quality assurance for assembled COMS eye plaques using a pinhole gamma camera. , 2008, Medical physics.
[18] F. Mourtada,et al. TU‐C‐AUD‐06: Calculation of the Dose Distribution Around a Commercially Available 125I Brachytherapy Source Via a Multi‐Group Discrete Ordinates Method , 2007 .
[19] F. Billson,et al. A thin I-125 seed eye plaque to treat intraocular tumors using an acrylic insert to precisely position the sources. , 1990, International journal of radiation oncology, biology, physics.
[20] G. Ibbott,et al. On the use of apparent activity (Aapp) for treatment planning of 125I and 103Pd interstitial brachytherapy sources: recommendations of the American Association of Physicists in Medicine radiation therapy committee subcommittee on low-energy brachytherapy source dosimetry. , 1999, Medical physics.
[21] B. Damato,et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. , 2005, International journal of radiation oncology, biology, physics.
[22] J. Williamson,et al. Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 interstitial sources: dosimetry and calibration changes: recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. , 1999, Medical physics.
[23] P. Finger,et al. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy. , 2007, Archives of ophthalmology.
[24] Z. Petrovich,et al. Backscatter measurements from a single seed of 125I for ophthalmic plaque dosimetry. , 1988, Medical physics.
[25] M. Astrahan,et al. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert. , 2005, Medical physics.
[26] D. Followill,et al. A reanalysis of the Collaborative Ocular Melanoma Study Medium Tumor Trial eye plaque dosimetry. , 2002, International journal of radiation oncology, biology, physics.
[27] Z. Petrovich,et al. An interactive treatment planning system for ophthalmic plaque radiotherapy. , 1990, International journal of radiation oncology, biology, physics.
[28] D. Harder,et al. Dosimetry and physical treatment planning for iodine eye plaque therapy. , 1991, International journal of radiation oncology, biology, physics.
[29] E. Gragoudas,et al. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. , 2002, Transactions of the American Ophthalmological Society.
[30] R. S. Hinks,et al. MR technique for localization and verification procedures in episcleral brachytherapy. , 1989, International journal of radiation oncology, biology, physics.
[31] J. Fontanesi,et al. Treatment of choroidal melanoma with I-125 plaque. , 1993, International journal of radiation oncology, biology, physics.
[32] J F Williamson,et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. , 2000, Medical physics.
[33] L. Muren,et al. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. , 2001, International journal of radiation oncology, biology, physics.
[34] S. Chiu‐Tsao,et al. Dosimetry for 125I seed (model 6711) in eye plaques. , 1993, Medical physics.
[35] S. Garelli,et al. The determination of dose characteristics of ruthenium ophthalmic applicators using radiochromic film. , 1997, Medical physics.
[36] M. Rivard,et al. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function. , 2012, Medical physics.
[37] B. Hawkins. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. , 2004, American journal of ophthalmology.
[38] P. Finger. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. , 2001, American journal of ophthalmology.
[39] C. Pavlin,et al. Management of iris melanomas with 125Iodine plaque radiotherapy. , 2010, American journal of ophthalmology.
[40] J. Kongerud,et al. Side effects of photon and proton radiotherapy for ocular melanoma. , 1997, Frontiers of radiation therapy and oncology.
[41] J. Earle,et al. Choroidal melanoma treatment with iodine 125 brachytherapy. , 1987, Archives of ophthalmology.
[42] M. Casebow. The calculation and measurement of exposure distributions from 60 Co ophthalmic applicators. , 1971, The British journal of radiology.
[43] M. Galin,et al. Radiation therapy of choroidal melanoma. , 1977, Transactions of the ophthalmological societies of the United Kingdom.
[44] Ravinder Nath,et al. Erratum: “Supplement to the 2004 update of the AAPM Task Group No. 43 Report” [Med. Phys. 34, 2187–2205 (2007)] , 2010 .
[45] M D Evans,et al. Tumor localization using fundus view photography for episcleral plaque therapy. , 1993, Medical physics.
[46] E. Sternick,et al. Effect of gold shielding on the dosimetry of an 125I seed at close range. , 1988, Medical physics.
[47] A. Wu,et al. Film dosimetry analyses on the effect of gold shielding for iodine-125 eye plaque therapy for choroidal melanoma. , 1990, Medical physics.
[48] Z. Petrovich,et al. Conformal episcleral plaque therapy. , 1997, International journal of radiation oncology, biology, physics.
[49] D. Rogersb,et al. More accurate fitting of 125 I and 103 Pd radial dose functions , 2008 .
[50] F. Mourtada,et al. 106Ru/106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study. , 2005, Radiation protection dosimetry.
[51] P. Levendag,et al. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. , 2004, International journal of radiation oncology, biology, physics.
[52] R M Thomson,et al. Monte Carlo dosimetry for I125 and Pd103 eye plaque brachytherapy. , 2008, Medical physics.
[53] J. Earle,et al. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma , 2002 .
[54] S. Seregard. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients. , 1999, Acta ophthalmologica Scandinavica.
[55] P. Finger,et al. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. , 2009, Ophthalmology.
[56] Mark J Rivard,et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. , 2007, Brachytherapy.
[57] J. Earle,et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. , 2003, International journal of radiation oncology, biology, physics.
[58] S. Logani,et al. Gamma Knife radiosurgery in the treatment of ocular melanoma. , 1993, Stereotactic and functional neurosurgery.
[59] R. Pötter,et al. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981-1989. , 1997, Frontiers of radiation therapy and oncology.
[60] M. Rivard,et al. COMS eye plaque brachytherapy dosimetry simulations for P103d, I125, and C131s. , 2008, Medical physics.
[61] T. Kivelä,et al. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. , 2004, Investigative ophthalmology & visual science.
[62] R. Rosen,et al. A 3-dimensional ultrasound C-scan imaging technique for optic nerve measurements. , 2004, Ophthalmology.
[63] P. Finger. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). , 2008, International journal of radiation oncology, biology, physics.
[64] D Flühs,et al. Direct reading measurement of absorbed dose with plastic scintillators--the general concept and applications to ophthalmic plaque dosimetry. , 1996, Medical physics.
[65] Mark J Rivard,et al. Anniversary paper: past and current issues, and trends in brachytherapy physics. , 2008, Medical physics.
[66] J. Scruggs. Malignant melanoma of the uvea. , 1960, American journal of ophthalmology.
[67] W. Butler,et al. Supplement to the 2004 update of the AAPM Task Group No. 43 Report. , 2007, Medical physics.
[68] E. Schuster,et al. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.
[69] P. Finger. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy , 2000, The British journal of ophthalmology.
[70] P. Finger,et al. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. , 2010, American journal of ophthalmology.
[71] P. Finger. Finger’s “slotted” eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours , 2007, British Journal of Ophthalmology.
[72] P. Finger,et al. Palladium 103 (103Pd) plaque radiation therapy for circumscribed choroidal hemangioma with retinal detachment. , 2004, Archives of ophthalmology.
[73] F. Kruse,et al. [Transplantation of amniotic membrane for reconstruction of the eye surface]. , 1998, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[74] S. Chiu‐Tsao,et al. 125I eye plaque dose distribution including penumbra characteristics. , 1996, Medical physics.
[75] L. Anderson,et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .
[76] R Pötter,et al. A linac-based stereotactic irradiation technique of uveal melanoma. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[77] F. Mourtada,et al. Calculation of beta-ray dose distributions from ophthalmic applicators and comparison with measurements in a model eye. , 2001, Medical physics.
[78] O. Pastyr,et al. Stereotactically guided convergent beam irradiation with a linear accelerator: Localization-technique , 1989, Acta Neurochirurgica.
[79] P. Finger,et al. Anterior segment tumors: current concepts and innovations. , 2003, Survey of ophthalmology.
[80] J. Anderson,et al. Radioactive iodine-125 as a therapeutic radiation source for management of intraocular tumors. , 1981, Transactions of the American Ophthalmological Society.
[81] P. Finger. Finger's amniotic membrane buffer technique: protecting the cornea during radiation plaque therapy. , 2008, Archives of ophthalmology.
[82] E. W. Shrigley. Medical Physics , 1944, British medical journal.
[83] P. Finger,et al. Palladium 103 ophthalmic plaque radiotherapy. , 1991, Archives of ophthalmology.
[84] F. Mourtada,et al. Dosimetry of beta-ray ophthalmic applicators: comparison of different measurement methods. , 2001, Medical physics.
[85] P L Carson,et al. Real-time B-mode ultrasound quality control test procedures. Report of AAPM Ultrasound Task Group No. 1. , 1998, Medical physics.
[86] M. Rivard,et al. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs. , 2008, Brachytherapy.
[87] J. Duker,et al. Dose de-escalation with gamma knife radiosurgery in the treatment of choroidal melanoma. , 2009, International journal of radiation oncology, biology, physics.
[88] F. Alessandrini,et al. Stereotactic radiosurgery of uveal melanomas: preliminary results with Gamma Knife treatment. , 1995, Stereotactic and functional neurosurgery.
[89] W. Butler,et al. Erratum: Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations (Medical Physics (2004) 31 (633-674)) , 2004 .
[90] S. Chiu‐Tsao,et al. Monte Carlo dosimetry for 125I and 60Co in eye plaque therapy. , 1986, Medical physics.
[91] I. Kaplan,et al. Radiation Therapy , 2006 .
[92] H. Atkins,et al. Irradiation of choroidal melanoma with iodine 125 ophthalmic plaque. , 1980, Archives of ophthalmology.
[93] A. Pavlick,et al. Systemic Bevacizumab (Avastin) for Exudative Retinal Detachment Secondary to Choroidal Melanoma , 2011, European journal of ophthalmology.
[94] R. E. Christensen,et al. Fluorescein angiography of choroidal melanomas. , 1970, Archives of ophthalmology.
[95] J. Williamson,et al. Monte Carlo-aided dosimetry of the theragenics TheraSeed model 200 103Pd interstitial brachytherapy seed. , 2002, Medical physics.
[96] Radiation Protection of Persons Living Close to Patients with Radioactive Implants , 2010, Strahlentherapie und Onkologie.
[97] B. Fernandes,et al. Management of iris melanomas with 125 iodine plaque radiotherapy , 2010 .
[98] R. Kline. Comments on “Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group 43” [Med. Phys. 22, 209–234 (1995)] , 1996 .
[99] G. Starkschall,et al. American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning. , 1998, Medical physics.
[100] J. Palta,et al. Comprehensive QA for Radiation Oncology , 1994 .
[101] P. Finger,et al. Abstract of ASTRO scientific papers to be presentedPalladium-103 versus iodine-125 for ophthalmic plaque radiotherapy , 1992 .
[102] P. Finger,et al. Long-term results of iodine 125 irradiation of uveal melanoma. , 1992, Ophthalmology.
[103] J. Earle,et al. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. , 1987, Archives of ophthalmology.
[104] N. Willich,et al. Does the Imaging Method Have an Influence on the Measured Tumor Height in Ruthenium Plaque Therapy of Uveal Melanoma? , 2005, Strahlentherapie und Onkologie.
[105] R. Liščák,et al. Radiosurgery in ocular disorders: clinical applications. , 2007, Progress in neurological surgery.
[106] J. Harbour,et al. Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. , 2003, Ophthalmology.
[107] G. Lundell,et al. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. , 2005, Ophthalmology.
[108] C. Moy,et al. Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14. , 2001, Controlled clinical trials.
[109] T. Kivelä,et al. Ocular complications after iodine brachytherapy for large uveal melanomas. , 2004, Ophthalmology.
[110] D. Shackleton,et al. Improved iodine-125 plaque design in the treatment of choroidal malignant melanoma. , 1992, The British journal of ophthalmology.
[111] P. Finger,et al. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy. , 2012, International journal of radiation oncology, biology, physics.
[112] P. Rama,et al. Gamma knife radiosurgery for uveal melanoma: 12 years of experience , 2008, British Journal of Ophthalmology.
[113] M. Astrahan. A patch source model for treatment planning of ruthenium ophthalmic applicators. , 2003, Medical physics.
[114] P. Finger,et al. Subfoveal choroidal melanoma: pretreatment characteristics and response to plaque radiation therapy. , 2011, Archives of ophthalmology.
[115] P Gastaud,et al. Results of proton therapy of uveal melanomas treated in Nice. , 1999, International journal of radiation oncology, biology, physics.
[116] H. Boldt,et al. I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30. , 2009, Ophthalmology.
[117] P. Finger,et al. High-frequency ultrasound measurements of the normal ciliary body and iris. , 2011, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[118] Stefan Sacu,et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. , 2011, International journal of radiation oncology, biology, physics.
[119] K. Weaver,et al. The dosimetry of 125I seed eye plaques. , 1986, Medical physics.
[120] M. Wilson,et al. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. , 1999, Ophthalmology.
[121] D. Char,et al. Ten-year follow-up of helium ion therapy for uveal melanoma. , 1998, American journal of ophthalmology.
[122] P. Finger,et al. Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy. , 2011, International journal of radiation oncology, biology, physics.
[123] M. Rivard,et al. Enhancements to commissioning techniques and quality assurance of brachytherapy treatment planning systems that use model-based dose calculation algorithms. , 2010, Medical physics.
[124] A. Lichter,et al. A new inexpensive customized plaque for choroidal melanoma iodine-125 plaque therapy. , 1989, Ophthalmology.
[125] A. Harnett,et al. An iodine-125 plaque for radiotherapy of the eye: manufacture and dosimetric considerations. , 1988, The British journal of radiology.
[126] R. F. Moore. CHOROIDAL SARCOMA TREATED BY THE INTRAOCULAR INSERTION OF RADON SEEDS , 1930, The British journal of ophthalmology.
[127] D. Shackleton,et al. The treatment of ophthalmic tumours with low-energy sources. , 1976, The British journal of radiology.
[128] M. Zaider,et al. The three-dimensional scintillation dosimetry method: test for a 106Ru eye plaque applicator , 2005, Physics in medicine and biology.
[129] J. Cygler,et al. Effects of gold and silver backings on the dose rate around an 125I seed. , 1990, Medical physics.
[130] H. Ishikawa,et al. Iris and ciliary body melanomas: ultrasound biomicroscopy with histopathologic correlation. , 2000, Archives of ophthalmology.
[131] J. Palta,et al. Comprehensive QA for radiation oncology: report of AAPM Radiation Therapy Committee Task Group 40. , 1994, Medical physics.
[132] J. Hokkanen,et al. Theoretical calculations of dose distributions for beta-ray eye applicators. , 1997, Medical physics.
[133] Z. Petrovich,et al. Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using iridium-192 and iodine-125 seeds. , 1988, International journal of radiation oncology, biology, physics.
[134] M. Astrahan. Improved treatment planning for COMS eye plaques. , 2005, International journal of radiation oncology, biology, physics.
[135] F. Kruse,et al. Amniotic membrane transplantation for ocular surface reconstruction , 1998, Der Ophthalmologe.
[136] J. Williamson,et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2003, Medical physics.
[137] J. Meli,et al. The effect of lead, gold, and silver backings on dose near 125I seeds. , 1993, Medical physics.
[138] C. Shields,et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications , 2003 .
[139] I. Constable,et al. Proton irradiation of small choroidal malignant melanomas. , 1977, American journal of ophthalmology.
[140] R. Eaglejr. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. , 2006, Archives of ophthalmology.
[141] S. Chiu‐Tsao,et al. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant. , 2010, Brachytherapy.
[142] Zuofeng Li,et al. Monte Carlo and experimental dosimetry of an I125 brachytherapy seed. , 2006, Medical physics.
[143] F. Davidorf,et al. Radiotherapy of malignant melanoma of the choroid. , 1976, Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology.
[144] P. Finger,et al. Intravitreous ranibizumab (lucentis) for radiation maculopathy. , 2010, Archives of ophthalmology.
[145] M Saiful Huq,et al. Third-party brachytherapy source calibrations and physicist responsibilities: report of the AAPM Low Energy Brachytherapy Source Calibration Working Group. , 2008, Medical physics.
[146] R. Kline,et al. The generalized geometry of eye plaque therapy. , 1988, Medical physics.
[147] B. Hawkins. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. , 2006, Archives of ophthalmology.
[148] F Ballester,et al. Dosimetric study of the 15 mm ROPES eye plaque. , 2004, Medical physics.
[149] L. Israël,et al. [Malignant melanoma of the uvea]. , 1993, Bulletin du cancer.
[150] M Goitein,et al. Proton beam irradiation of uveal melanomas. Results of 5 1/2-year study. , 1982, Archives of ophthalmology.
[151] C. Shields. I-125 Brachytherapy for Choroidal Melanoma: Photographic and Angiographic Abnormalities: The Collaborative Ocular Melanoma Study: COMS Report No. 30 , 2010 .
[152] Anders Ahnesjö,et al. Optimization of the computational efficiency of a 3D, collapsed cone dose calculation algorithm for brachytherapy. , 2008, Medical physics.
[153] P. Finger,et al. A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. , 2012, Ophthalmology.
[154] Luc Beaulieu,et al. The evolution of brachytherapy treatment planning. , 2009, Medical physics.
[155] Ravinder Nath,et al. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy. , 2005, Medical physics.
[156] R. Iezzi,et al. Three-dimensional ultrasound for the measurement of choroidal melanomas. , 2001, Archives of ophthalmology.
[157] J. Earle,et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. , 2006, Archives of ophthalmology.
[158] P. Finger. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. , 2007, American journal of ophthalmology.
[159] M. Rotman,et al. Radiotherapy of Choroidal Melanoma with Iodine 125 , 1980, Ophthalmology.
[160] J. O'Brien,et al. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. , 2006, Archives of ophthalmology.
[161] C. Greven,et al. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study. , 2008, International journal of radiation oncology, biology, physics.
[162] J. Sisterson. Ion beam therapy in 2004 , 2005 .
[163] Ann Schalenbourg,et al. Eye retention after proton beam radiotherapy for uveal melanoma. , 2003, International journal of radiation oncology, biology, physics.
[164] J. Duker,et al. BEDVH-A method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants. , 2012, Medical physics.
[165] M. Rotman,et al. Computerized Dosimetry of 60Co Ophthalmic Applicators1 , 1972 .
[166] P. Finger,et al. Eye cancer related glaucoma: current concepts. , 2009, Survey of ophthalmology.
[167] Anders Ahnesjö,et al. Accounting for high Z shields in brachytherapy using collapsed cone superposition for scatter dose calculation. , 2003, Medical physics.
[168] P. Finger,et al. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. , 2007, Archives of ophthalmology.
[169] Moore Rf. CHOROIDAL SARCOMA TREATED BY THE INTRAOCULAR INSERTION OF RADON SEEDS. , 1930 .
[170] R. Taylor,et al. More accurate fitting of I125 and Pd103 radial dose functions. , 2008, Medical physics.
[171] R. Taylor,et al. An EGSnrc Monte Carlo-calculated database of TG-43 parameters. , 2008, Medical physics.
[172] M. Zaider,et al. The measurement of three dimensional dose distribution of a ruthenium-106 ophthalmological applicator using magnetic resonance imaging of BANG polymer gels , 2000, Proceedings of the 22nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (Cat. No.00CH37143).
[173] J. Overgaard,et al. Visual outcome, local tumour control, and eye preservation after 106Ru/Rh brachytherapy for choroidal melanoma , 2006, Acta oncologica.
[174] D. Rogers,et al. Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy. , 2010, International journal of radiation oncology, biology, physics.